UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire09-04

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:

H.C. Wainwright 27th Annual Global Investment Conference
Date:	Tuesday, September 9, 2025
Format:	1x1 Investor Meetings Only

Morgan Stanley 23rd Annual Global Healthcare Conference
Date:	Wednesday, September 10, 2025
Format:	Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2564731460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 04:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564731460","market":"hk","top_or_hot":-1,"title":"UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>HIGH POINT, N.C., Sept.  03, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:</p> <table><tr><td colspan=\"2\"><strong>H.C. Wainwright 27th Annual Global Investment Conference</strong><br/></td></tr><tr><td>Date:</td><td>Tuesday, September 9, 2025</td></tr><tr><td>Format:</td><td>1x1 Investor Meetings Only</td></tr><tr><td> </td><td> </td></tr><tr><td colspan=\"2\"><strong><a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> 23rd Annual Global Healthcare Conference </strong></td></tr><tr><td>Date:</td><td>Wednesday, September 10, 2025</td></tr><tr><td>Format:</td><td>Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings</td></tr><tr><td> </td><td> </td></tr></table> <p><strong>About</strong> <strong>vTv</strong> <strong><a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong><br/>vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by <em>cadisegliatin</em>, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.</p> <p><strong>Investor Contact</strong><br/>John Fraunces<br/>LifeSci Advisors, LLC<br/>jfraunces@lifesciadvisors.com</p> <p><strong>Media Contact</strong><br/>Caren Begun<br/>TellMed Strategies<br/>201-396-8551<br/>caren.begun@tmstrat.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/OTZjY2VlNzUtNmNlNS00Y2NjLWIyZWEtM2U1MGEwODNhNTFjLTEwMzEzNjctMjAyNS0wOS0wMy1lbg==/tiny/vTv-Therapeutics-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-09-04 04:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>HIGH POINT, N.C., Sept.  03, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:</p> <table><tr><td colspan=\"2\"><strong>H.C. Wainwright 27th Annual Global Investment Conference</strong><br/></td></tr><tr><td>Date:</td><td>Tuesday, September 9, 2025</td></tr><tr><td>Format:</td><td>1x1 Investor Meetings Only</td></tr><tr><td> </td><td> </td></tr><tr><td colspan=\"2\"><strong><a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> 23rd Annual Global Healthcare Conference </strong></td></tr><tr><td>Date:</td><td>Wednesday, September 10, 2025</td></tr><tr><td>Format:</td><td>Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings</td></tr><tr><td> </td><td> </td></tr></table> <p><strong>About</strong> <strong>vTv</strong> <strong><a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong><br/>vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by <em>cadisegliatin</em>, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.</p> <p><strong>Investor Contact</strong><br/>John Fraunces<br/>LifeSci Advisors, LLC<br/>jfraunces@lifesciadvisors.com</p> <p><strong>Media Contact</strong><br/>Caren Begun<br/>TellMed Strategies<br/>201-396-8551<br/>caren.begun@tmstrat.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/OTZjY2VlNzUtNmNlNS00Y2NjLWIyZWEtM2U1MGEwODNhNTFjLTEwMzEzNjctMjAyNS0wOS0wMy1lbg==/tiny/vTv-Therapeutics-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/09/03/3144092/0/en/UPDATE-vTv-Therapeutics-to-Participate-in-Upcoming-September-Investor-Conferences.html","article_id":"2564731460","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564731460","pubTimestamp":1756933020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"HIGH POINT, N.C., Sept.  03, 2025  (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.(Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4588":"碎股","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","VTVT":"vTv Therapeutics Inc.","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4581":"高盛持仓","LU0971096721.USD":"富达环球金融服务 A","LU1548497426.USD":"安联环球人工智能AT Acc","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0106831901.USD":"贝莱德世界金融基金A2","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0882574139.USD":"富达环球消费行业基金A ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4139":"生物科技","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4127":"投资银行业与经纪业","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","BK4516":"特朗普概念","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","BK4504":"桥水持仓","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC"},"translate_title":"更新--vTv Therapeutics将参加即将举行的9月投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTVT":1},"content_text":"HIGH POINT, N.C., Sept.  03, 2025  (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1x1 Investor Meetings Only  Morgan Stanley 23rd Annual Global Healthcare Conference Date:Wednesday, September 10, 2025Format:Fireside Chat Time: 2:35 PM - 3:10 PM EST and 1x1 Investor Meetings   About vTv TherapeuticsvTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X. Investor ContactJohn FrauncesLifeSci Advisors, LLCjfraunces@lifesciadvisors.com Media ContactCaren BegunTellMed Strategies201-396-8551caren.begun@tmstrat.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564731460","isCrawlerRequest":true}